News Releases
May 17 2004
Peregrine's Vascular Targeting Agent Technology Presented at Second International Conference on Vascular Targeting
May 11 2004
Peregrine Pharmaceuticals Provides Company Update
Apr 28 2004
Peregrine Pharmaceuticals Finalizes Agreement to Evaluate VTA Platform for Treatment of Ocular Disease
Mar 30 2004
Peregrine Pharmaceuticals Announces Publication of Data Related to Its Tumor Necrosis Therapy Technology Platform
Mar 30 2004
Peregrine's VTA Inhibits Growth of Breast Cancer Tumor Metastases by up to 58 Percent
Mar 30 2004
Peregrine's Anti-Angiogenesis Agent Inhibits Growth of Blood Vessels by up to 85% in Breast Cancer Tumor Metastases
Mar 29 2004
Peregrine's VTA & Docetaxel Combination Therapy Inhibits Human Breast Cancer Growth by 93% in Pre-Clinical Studies
Mar 25 2004
Peregrine Pharmaceuticals Presents Summary of Clinical Experience of Tumor Necrosis Therapy
Mar 23 2004
Peregrine Pharmaceuticals Announces Grant of Broad Claims in Europe for its Vascular Targeting Agent Technology
Mar 10 2004
Peregrine Pharmaceuticals Announces Publication of Data Related to its Tumor Necrosis Therapy Technology Platform